[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-339461-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-339461-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","signaling-pathways-in-liver-cancer-pathogenesis-and-targeted-therapy","Signaling pathways in liver cancer: pathogenesis and targeted therapy","","Liver cancer remains among the most prevalent malignancies worldwide, characterized by late diagnosis due to subtle onset and high mortality. Systemic targeted therapies are therefore crucial for improving outcomes. This review provides an in-depth discussion of signaling pathways implicated in liver cancer pathogenesis, with emphasis on hepatocellular carcinoma (HCC), and summarizes targeted inhibitors under investigation or in clinical use. Particular focus is placed on tyrosine kinase inhibitors and mechanisms of resistance.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/signaling-pathways-in-liver-cancer-pathogenesis-and-targeted-therapy/339461/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/signaling-pathways-in-liver-cancer-pathogenesis-and-targeted-therapy/339461.png","ImageObject",300,407,{"name":42,"@type":43},"Hazel","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-05","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is liver cancer often diagnosed at a late stage?","Question",{"text":63,"@type":64},"Liver cancer has a subtle onset, so it is commonly detected late, when surgical interventions are no longer feasible.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What limits the clinical use of sorafenib in targeted therapy?",{"text":68,"@type":64},"Its application is greatly limited by drug resistance, a key challenge in treatment.",{"name":70,"@type":61,"acceptedAnswer":71},"Which targeted agents are emphasized for HCC treatment in the review?",{"text":72,"@type":64},"The review focuses on tyrosine kinase inhibitors (TKIs), especially their roles and resistance mechanisms during HCC treatment.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},339461,1790336624,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":97,"preview_urls":146},137441390410,"https://ap-avatar.wpscdn.com/avatar/2000252f4ab5702993?_k=1776741390130283984","Xue et al. Molecular Biomedicine (2024) 5:20 [https://doi.org/10.1186/s43556-024-00184-0](https://doi.org/10.1186/s43556-024-00184-0)  \nMolecular Biomedicine  \n REVIEW Open Access  \nSignaling pathways in liver cancer: pathogenesis and targeted therapy  \nYangtao Xue1,3,4,5,6†, Yeling Ruan1,3,4,5,6†, Yali Wang1,3,4,5,6, Peng Xiao2* and Junjie Xu1,3,4,5,6*  \nAbstract  \nLiver cancer remains one of the most prevalent malignancies worldwide with high incidence and mortality rates. Due to its subtle onset, liver cancer is commonly diagnosed at a late stage when surgical interventions are no longer feasible. This situation highlights the critical role of systemic treatments, including targeted therapies, in bettering patient outcomes. Despite numerous studies on the mechanisms underlying liver cancer, tyrosine kinase inhibitors (TKIs) are the only widely used clinical inhibitors, represented by sorafenib, whose clinical application is greatly limited by the phenomenon of drug resistance. Here we show an in-depth discussion of the signaling pathways frequently implicated in liver cancer pathogenesis and the inhibitors targeting these pathways under investigation or already in use in the management of advanced liver cancer. We elucidate the oncogenic roles of these pathways in liver cancer especially hepatocellular carcinoma (HCC), as well as the current state of research on inhibitors respectively. Given that TKIs represent the sole class of targeted therapeutics for liver cancer employed in clinical practice, we have particularly focused onTKIs and the mechanisms ofthe commonly encountered phenomena of its resistance during HCC treatment. This necessitates the imperative development of innovative targeted strategies and the urgency of overcoming the existing limitations. This review endeavors to shed light on the utilization of targeted therapy in advanced liver cancer, with a vision to improve the unsatisfactory prognostic outlook for those patients.  \nKeywords Liver cancer, Hepatocellular carcinoma (HCC), Targeted therapy, Signaling pathways, Sorafenib  \n†Yangtao Xue andYeling Ruan contributed equally to this work and share first authorship.  \n*Correspondence: Peng Xiao [tulipxp@zju.edu.cn](tulipxp@zju.edu.cn)[ ](tulipxp@zju.edu.cn)Junjie Xu [walter235@zju.edu.cn](walter235@zju.edu.cn)  \n1 Key Laboratory of Laparoscopic Technology of Zhejiang Province, Department of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China  \n2 Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China  \n3 National Engineering Research Center of Innovation and Application of Minimally Invasive Instruments, Hangzhou 310016, China  \n4 Zhejiang Minimal Invasive Diagnosis and Treatment Technology Research Center of Severe Hepatobiliary Disease, Zhejiang Research and Development Engineering Laboratory of Minimally Invasive Technology and Equipment, Hangzhou 310016, China  \n5 Zhejiang University Cancer Center, Hangzhou 310058, China  \n6 Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou 311121, China  \nIntroduction  \nAnnually, liver cancer emerges as a highly prevalent form of malignancy, resulting in a considerable amount of fatalities. In global cancer statistics for 2020, liver cancer stands as the sixth most frequently diagnosed typeof cancer. Hepatocellular carcinoma (HCC) accounts for almost 90% of the approximately 906,000 liver cancer cases diagnosed globally [1, 2]. Cholangiocarcinoma (CCA) is the second most prevalent primary liver malignancy after HCC and is categorized into three subtypes: distal CCA (dCCA), perihilar CCA (pCCA), and intrahepatic CCA (iCCA) [3]. A recent study conducted in the US reported an increasing trend in the incidence of CCA with age [4]. Many ongoing studies have focused primarily on HCC because of its high incidence among liver cancers. HCC ranks third in cancer-related mortality, with a merely 18% of 5-year survival rate [5]","cbCaie9zQ58GowVV","https://ap.wps.com/l/cbCaie9zQ58GowVV","pdf",2642350,43,"English","# Introduction\n## Disease burden and subtypes\n## Signaling pathways and mechanisms","[{\"question\":\"Why is liver cancer often diagnosed at a late stage?\",\"answer\":\"Liver cancer has a subtle onset, so it is commonly detected late, when surgical interventions are no longer feasible.\"},{\"question\":\"What limits the clinical use of sorafenib in targeted therapy?\",\"answer\":\"Its application is greatly limited by drug resistance, a key challenge in treatment.\"},{\"question\":\"Which targeted agents are emphasized for HCC treatment in the review?\",\"answer\":\"The review focuses on tyrosine kinase inhibitors (TKIs), especially their roles and resistance mechanisms during HCC treatment.\"}]","Signaling pathways in liver cancer: pathogenesis and targeted therapy | PDF",1790030394,108,[147,151,155,159,163],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d4c3dad11fefab4aa3cf87bbe8297f86.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/72798e2be7ae102da42e0add51f7b501.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/90c01d55d7aa0e28f23d63c7c3e95a18.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cc67b27aef707a5a5235deb592b071b9.webp",980,1301,{"page_no":97,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/979b3c1447a2ec7721f64dd9312df04b.webp",979,1300]